|
|
You are subscribed to receive research study announcements from the National Institutes of Health (NIH) Clinical Center. To learn more about this NIH study #17-H-0019, or other studies, please call us at 866-444-1132.
Researching a more effective treatment to prevent relapse for severe aplastic anemia (SAA)
Aplastic anemia is a rare and serious blood disorder. Patients with severe aplastic anemia
commonly receive cyclosporine to help improve blood counts. When cyclosporine treatment
stops, the disease may return in 1 in 3 people. Researchers at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland are studying if sirolimus, an immunosuppressant medication, can help prevent a relapse in patients
diagnosed with severe aplastic anemia after stopping cyclosporine treatment.
What is involved?
Participants will:
- Be randomly assigned to two groups:
- one group will stop taking cyclosporine and receives sirolimus for 3 months;
- second group will stop taking cyclosporine and not receive any medication
but will be closely monitored
- Receive a full medical history, physical examination, and bone marrow biopsy
- Be asked to participate for up to five years
- Receive study related medication, tests, and procedures at no cost
To be eligible for this study, you must:
- Be 2 years or older
- Have responded to immunosuppressive therapy that includes cyclosporine and
continue on cyclosporine.
|
|
|
For more information:
NIH Clinical Center Office of Patient Recruitment
866-444-1132
TTY users dial 7-1-1
ccopr@nih.gov
https://go.usa.gov/xnuz3
Study #17-H-0019
Follow us on Instagram @nih_ccopr
The NIH Clinical Center, America’s Research Hospital located in Bethesda, MD
Metro red line (Medical Center stop)
|
|
|
|
